Annals of Diagnostic Pathology
Volume 11, Issue 6 , Pages 402-406 , December 2007

Immunohistochemical detection of X-linked inhibitor of apoptosis in head and neck squamous cell carcinoma

  • Chandandeep Nagi, MD

      Affiliations

    • Department of Pathology, Mount Sinai School of Medicine, New York, NY 10029, USA
    • ,
  • Guang-Qing Xiao, MD

      Affiliations

    • Department of Pathology, Mount Sinai School of Medicine, New York, NY 10029, USA
    • ,
  • Gan Li, PhD

      Affiliations

    • Department of Pathology, Mount Sinai School of Medicine, New York, NY 10029, USA
    • ,
  • Eric Genden, MD

      Affiliations

    • Department of Otolaryngology, Mount Sinai School of Medicine, New York, NY 10029, USA
    • ,
  • David E. Burstein, MD

      Affiliations

    • Department of Pathology, Mount Sinai School of Medicine, New York, NY 10029, USA
    • Department of Oncologic Sciences, Mount Sinai School of Medicine, New York, NY 10029, USA
    • Corresponding Author InformationCorresponding author. Department of Pathology, Mount Sinai School of Medicine, Box 1194, New York, NY 10029, USA. Tel.: +1 212 241 0364; fax: +1 212 289 2899.

References 

  1. Salvesen GS, Duckett CS. IAP proteins: blocking the road to death's door. Nat Rev Mol Cell Biol. 2002;3:401–410
  2. Schimmer AD, Dalili S, Batey RA, Riedl SJ. Targeting XIAP for the treatment of malignancy. Cell Death Differ. 2006;13:179–188
  3. Holcik M, Gibson H, Korneluk RG. XIAP: apoptotic brake and promising therapeutic target. Apoptosis. 2001;6:253–261
  4. Berezovskaya O, Schimmer AD, Glinskii AB, Pinilla C, Hoffman RM, Reed JC, et al. Increased expression of apoptosis inhibitor protein XIAP contributes to anoikis resistance of circulating human prostate cancer metastasis precursor cells. Cancer Res. 2005;65:2378–2386
  5. Holcik M, Yeh C, Korneluk RG, Chow T. Translational upregulation of X-linked inhibitor of apoptosis (XIAP) increases resistance to radiation induced cell death. Oncogene. 2000;19:4174–4177
  6. Tong QS, Zheng LD, Wang L, Zeng FQ, Chen FM, Dong JH, et al. Downregulation of XIAP expression induces apoptosis and enhances chemotherapeutic sensitivity in human gastric cancer cells. Cancer Gene Ther. 2005;12:509–514
  7. Chawla-Sarkar M, Bae SI, Reu FJ, Jacobs BS, Lindner DJ, Borden EC. Downregulation of Bcl-2, FLIP or IAPs (XIAP and survivin) by siRNAs sensitizes resistant melanoma cells to Apo2L/TRAIL-induced apoptosis. Cell Death Differ. 2004;11:915–923
  8. Sasaki H, Sheng Y, Kotsuji F, Tsang BK. Down-regulation of X-linked inhibitor of apoptosis protein induces apoptosis in chemoresistant human ovarian cancer cells. Cancer Res. 2000;60:5659–5666
  9. McManus DC, Lefebvre CA, Cherton-Horvat G, St-Jean M, Kandimalla ER, Agrawal S, et al. Loss of XIAP protein expression by RNAi and antisense approaches sensitizes cancer cells to functionally diverse chemotherapeutics. Oncogene. 2004;23:8105–8117
  10. Harlin H, Reffey SB, Duckett CS, Lindsten T, Thompson CB. Characterization of XIAP-deficient mice. Mol Cell Biol. 2001;21:3604–3608
  11. Muris JJ, Cillessen SA, Vos W, van Houdt IS, Kummer JA, van Krieken J, et al. Immunohistochemical profiling of caspase signaling pathways predicts clinical response to chemotherapy in primary nodal diffuse large B-cell lymphomas. Blood. 2005;105:2916–2923
  12. Tamm I, Richter S, Scholz F, Schmelz K, Oltersdorf D, Karawajew L, et al. XIAP expression correlates with monocytic differentiation in adult de novo AML: impact on prognosis. Hematol J. 2004;5:489–495
  13. Tamm I, Richter S, Oltersdorf D, Creutzig U, Harbott J, Scholz F, et al. High expression levels of x-linked inhibitor of apoptosis protein and survivin correlate with poor overall survival in childhood de novo acute myeloid leukemia. Clin Cancer Res. 2004;10:3737–3744
  14. Ramp U, Krieg T, Caliskan E, Mahotka C, Ebert T, Willers R, et al. XIAP expression is an independent prognostic marker in clear-cell renal carcinomas. Hum Pathol. 2004;35:1022–1028
  15. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell. 2000;100:57–70
  16. van Houten VM, Tabor MP, van den Brekel MW, et al. Mutated p53 as a molecular marker for the diagnosis of head and neck cancer. J Pathol. 2002;198:476–486
  17. Sharma J, Sen S, Mathur M, Bahadur S, Singh N. Combined evaluation of expression of telomerase, survivin, and anti-apoptotic Bcl-2 family members in relation to loss of differentiation and apoptosis in human head and neck cancers. Head Neck. 2004;26:733–740
  18. Anneroth G, Batsakis J, Luna M. Review of literature and a recommended system of malignancy grading in oral squamous cell carcinomas. Scand J Dent Res. 1987;95:229–249
  19. Whyte DA, Broton CE, Shillitoe EJ. The unexplained survival of cells in oral cancer: what is the role of p53?. J Oral Pathol Med. 2002;31:125–133
  20. Bannerji R, Kitada S, Flinn IW, et al. Apoptotic-regulatory and complement-protecting protein expression in chronic lymphocytic leukemia: relationship to in vivo rituximab resistance. J Clin Oncol. 2003;21:1466–1471
  21. Holcik M, Yeh C, Korneluk RG, et al. Translational upregulation of X-linked inhibitor of apoptosis (XIAP) increases resistance to radiation induced cell death. Oncogene. 2000;19:4174–4177
  22. Bhojani MS, Rossu BD, Rehemtulla A. TRAIL and anti-tumor responses. Cancer Biol Ther. 2003;2(Suppl 1):S71–S78
  23. Kamsteeg M, Rutherford T, Sapi E, Bozena Hanczaruk B, Shahabi S, Flick M, et al. Phenoxodiol—an isoflavone analog—induces apoptosis in chemoresistant ovarian cancer cells. Oncogene. 2003;22:2611–2620
  24. Rutherford T, O'Malley D, Makkenchery A, Baker L, Azodi M, Schwartz PE, et al. Phenoxodiol phase Ib/II study in patients with recurrent ovarian cancer that are resistant to second line chemotherapy. Am Assoc Cancer Res. 2005;95:Abs 4457

PII: S1092-9134(06)00170-5

doi: 10.1016/j.anndiagpath.2006.12.012

Annals of Diagnostic Pathology
Volume 11, Issue 6 , Pages 402-406 , December 2007

Article Tools

* Image Usage & Resolution